Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease

Catheterization and Cardiovascular Interventions

Volumn 50, Issue 2, 2000, Pages 245-254

  Kornowski, Ran ^a   Lansky, Alexandra J ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Angioplasty; Bypass surgery; Diabetes mellitus; Ischemic heart disease; Stents

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMAN; ISCHEMIC HEART DISEASE; RESTENOSIS; RISK FACTOR; STENT;

EID: 0034091581     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1522-726x(200006)50:2<245::aid-ccd22>3.0.co;2-p     Document Type: Article

References (66)

1. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535.
2. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87(Suppl 5):51-55.
3. Winocour PD, Richardson M, Kinglough-Rathbone RL. Continued platelet interaction with de-endotheliazed aorta associated with slower re-endothelization and more extensive intimal hyperplasia in spontaneously diabetic BB Wistar rats. Int J Exp Patol 1993;74:603-613.
4. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in cultures: delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985;34:621-627.
5. Kawano M, Koshikawa T, Kanzaki T, Morizaki N, Saito Y, Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β-receptor. Eur J Clin Invest 1993;23:84-90.
6. Kanzaki T, Shinomiya M, Ueda S, Morizaki N, Saito Y, Yoshida S. Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF β-receptor over-expression. Eur J Clin Invest 1994;24:377-381.
7. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cell. Circ Res 1975;36:319-327.
8. Pfefile B, Ditschuneit H. Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologica 1981;20:155-158.
9. Bornfeldt KE, Raines EW, Nakano T, Graves TN, Krebs EG, Ross R. Insulin like growth factor-1 and platelet derived growth factors-BB induce direct migration of human smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266-1274.
10. Murphy LJ, Ghahary A, Chakrabarti AS. Insulin regulation of IGF-1 expression in rat aorta. Diabetes 1990;39:657-662.
11. Banskota NK, Taub R, Zellner K, King JL. Insulin, insulin-like growth factor I and platelet derived growth factor interact additively in the induction of protoomcogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 1989;3:1183-1190.
12. McClain DA, Paterson AJ, Ross MD, Wei X. Glucose and glucoseamine regulate growth factors gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1992;89:8150-8154.
13. Lindner V, Reidy MA. Proliferation of smooth muscle cell after vascular injury is inhibited by antibody against fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
14. Brownlee M. Glycation and diabetes complications. Diabetes 1994;43:836-841.
15. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosilation induces selective transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease in diabetes and aging. Proc Natl Acad Sci 1990; 87:9010-9014.
16. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries - a possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984;310:175-177.
17. Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ. Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Hum Pathol 1987;18:1036-1042.
18. Kwon HM, Sangiorgi G, Ritman EL, Lerman A, McKenna C, Virmani R, Edwards WD, Holmes DR, Schwartz RS. Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol 1998;32:2072-2079.
19. Stein B, Weintraub WS, Gebhart SSP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS, Morris DC, King SB III. Influence of diabetes mellitus on early and late outcome after percutaneous transmural coronary angioplasty. Circulation 1995; 91:979-989.
20. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier J. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.
21. Halon DA, Merdler A, Flugelman MY, Shifroni G, Khader N, Shiran A, Shahla J, Lewis BS. Importance of diabetes mellitus and systemic hypertension rather than completeness of revascularization in determining long-term outcome after coronary balloon angioplasty (the LDCMC registry): Lady Davis Carmel Medical Center. Am J Cardiol 1998;82:547-553.
22. Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, Weiss AT, Hasin Y, Gotsman M. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study - Balloon Angioplasly Revascularization Investigation. J Am Coll Cardiol 1997;30:1420-1425.
23. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stealing in patients with diabetes mellitus. Ann Intern Med 1993;118:344-349.
24. Lau KW, Ding ZP, Johan A, Lim Y. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study. Am Heart J 1998;136:150-155.
25. Kornowski R, Mintz GS, Kent KM, Richard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serail intravascular study. Circulation 1997;95:1366-1369.
26. Van Belle E, Bauters C, Hubert E, Bodart JC, Abolmaali K, Meurice T, MacFadden EP, Lablanche JM, Bertrand M. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454-1460.
27. Savage MP, Fischman DL, Slota P, Rake R, Leon M, Schatz R, Moses J, Penn I, Nobuyoshi M, Heuser R, Goldberg S. Coronary intervention in the diabetic patient: improved outcome following stent implantation versus balloon angioplasty. J Am Coll Cardiol 1997;29(suppl A):188A.
28. Carrozza JP, Kalon KL, Neiman D, Kuntz RE, Cutlip DE. Diabetes mellitus is associated with adverse 6-month angiographic and clinical outcome following coronary stenting. Circulation 1998;98:179.
29. Joseph T, Fajadet J, Laurent JP, Jordan C, Cassagneau B, Laborde JC, Marco J. Implantation of coronary stents in diabetic patients: short- and medium-term clinical results. Arch Mal Coeur Vaiss 1998;91:715-720.
30. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-589.
31. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-1873.
32. Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992;41(suppl 2):32-35.
33. Getz GS. Reports on the workshop on diabetes and mechanisms of atherogenesis. Arteriosler Thromb 1993;13:459-464.
34. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998;97:1912-1920.
35. Lincoff AM, Tcheng JE, Cabot CF, Califf RM, Booth JE, Sapp S, Topol EJ. Marked benefit in diabetic patients treated with stent and abxiximab combination: 6 month outcome of the EPISTENT trial. J Am Coll Cardiol 1999:133:45A.
36. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: evaluation of Platelet IIb/IIIa Inhibition in stenting investigators. N Engl J Med 1999;341:319-27.
37. Marso S, Bhatt DL, Tanguay JF, Hammoud T, Sapp SK, Robbins MA, Kleiman NS. Synergy of stenting plus abciximab in diabetic patients: persistence throughout 1-year follow-up from EPISTENT. Circulation 1999;100:1365.
38. Bhatt DL, Marso SP, Lincoff MA, Wolski KE, Ellis SE, Topol EJ. Abciximab reduces death in diabetics following percutaneoius coronary intervention. Circulation 1999;100:167.
39. Steinhubl SR, Kottke-Marcchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Coller BS, Topol EJ, Lincoff MA. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999;100:1977-1982.
40. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997;96:1761-1769.
41. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, Krone RJ, Frye RL, Feit F. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-640.
42. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation 1999;99:847-851.
43. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96: 2551-2556.
44. O'Neill WW. Multivessel balloon angioplasty should be abandoned in diabetic patients! J Am Coll Cardiol 1998;31:20-22.
45. Gum PA, O'Keefe JH Jr, Borkon AM, Spertus JA, Bateman TM, McGraw JP, Sherwani K, Vacek J, McCallister BD. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997;96(Suppl):II7-II10.
46. Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB III. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998;31:10-19.
47. Morris JJ, Smith LR, Jones RH, Glower DD, Morris PB. Muhlbaier LH, Reves JG, Rankin JS. Influence of diabetes and mammary artery grafting on survival after coronary bypass.Circulation 1991:84(Suppl):III275-III284.
48. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years. Am J Cardiol 1994;74: 334-339.
49. Herlitz J, Wognsen GB, Emanuelsson H, Haglid M, Karlson BW, Karlsson T, Albertsson P, Westberg S. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 1996;19:698-703.
50. Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol 1998;81:7-11.
51. Serruys PW, Costa MA, Batriu A, van Boven AJ, Voudris V, Saunamaki K, Ribeiro VG, Rutsch W, Bett JH, Dubois-Rande JJ, de Valk V, Unger F. The influence of diabetes mellitues on clinical outcome following multivessel stenting or CABG in the ARTS trial. Circulation 1999;100:1364.
52. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Morris NB, Leon MB, Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
53. Waksman R, White LR, Chan R, Porrazo M, Bass B, Satler LF, Kent KM, Geirlach LM, Mehran R, Murphy M, Mintz GS, Leon MB. Intracoronary radiation therapy for patients with in-stent restenosis: 6 month follow-up of a randomized clinical study. Circulation 1998;98:1651.
54. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA. A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial. Int J Radiat Oncol Biol Phys 1998;42:1097-1104.
55. Moses JW, Leon MB, Lansky AJ, Wong CS, Gorgianni J, Nawaz DM, Kluck B, Firth B, Teirstein PS. Gamma intracoronary radiation reduces restenosis in diabetic patients within in-stent restenosis: results from the gamma-1 trial. Circulation 1999;100:167.
56. Kornowski R, Hong MK, Ragheb A, Bramwell O, Leon MB. Slow release Taxol coated GR-II stents reduce neointima formation in a porcine coronary in-stent restenosis model. Circulation 1997;96:1341.
57. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997 15;96:636-645.
58. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB III, Hamm CW, Puel J, Hueb W, Goy JJ, Rodriguez A. Metaanalysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-1189.
59. Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999;34:40-48.
60. Marso SP, Ellis SG, Tuzcu M, Whitlow PL, Franco I, Raymond RE, Topol EJ. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 1999;33:1269-1277.
61. Kornowski R, Mehran R, Hong MK, Satler LF, Pichard AD, Kent KM, Mintz GS, Waksman R, Laird JR, Lansky AJ, Bucher TA, Popma JJ, Leon MB. Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. Circulation 1998;97:1355-1361.
62. Elsner M, Walter D, Auch-Schwelk W, Schachinger V. Statin therapy in diabetic patients is associated with reduced clinical event rale and attenuated neoinitimal proliferation after coronary stenting. Circulation 1999;100:1365.
63. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-1820.
64. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242.
65. Schaper W, Buschmann I. Collateral circulation and diabetes. Circulation 1999;99:2224-2226.
66. Kornowski R, Hong MK, Leon MB. Current perspectives on direct myocardial revascularization. Am J Cardiol 1998:81:44E-48E.